2-氯-6-甲基-苯并噁唑 | 3621-83-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶唑类
• 中文名称: 2-氯-6-甲基-苯并噁唑
• 英文名称: 2-chloro-6-methylbenzo[d]oxazole
• 英文别名: 2-chloro-6-methyl-benzooxazole；2-chloro-6-methylbenzoxazole；2-chloro-6-methyl-1,3-benzoxazole
• CAS: 3621-83-8
• 化学式: C₈H₆ClNO
• 分子量: 167.595
• InChiKey: CLEOKTJHYLXEKQ-UHFFFAOYSA-N

物化性质

• 沸点：
  116-117 °C(Press: 10 Torr)
• 密度：
  1.311±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P264,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P362,P403+P233,P501
• 危险性描述：
  H315,H319,H335
• 储存条件：
  存储条件：室温、密闭保存，并保持干燥。

反应信息

• 作为反应物：
  描述：

  2-氯-6-甲基-苯并噁唑 在 sodium hydroxide 、 一水合肼 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 反应 1.0h， 生成 3-[Amino-(6-methyl-1,3-benzoxazol-2-yl)amino]propanenitrile
  参考文献：
  名称：

  3-[1-(2-Benzoxazolyl)hydrazino]propanenitrile derivatives: inhibitors of immune complex induced inflammation

  摘要：

  3-[1-(2-Benzoxazolyl)hydrazino]propanenitrile derivatives were evaluated in the dermal and pleural reverse passive Arthus reactions in the rat. In the pleural test these compounds were effective in reducing exudate volume and accumulation of white blood cells. This pattern of activity was similar to that of hydrocortisone and different from that of indomethacin. The structural requirements for inhibiting the Arthus reactions were studied by systematic chemical modification of 1. These structure-activity relationship studies revealed that nitrogen 1' of the hydrazino group is essential for activity and must be electron rich, whereas chemical modifications of other sites of 1 had only a modest effect on activity.

  DOI：

  10.1021/jm00117a010
• 作为产物：
  描述：

  6-甲基-1,3-苯并噁唑-2-硫醇 在 五氯化磷 作用下， 以 甲苯 为溶剂， 生成 2-氯-6-甲基-苯并噁唑
  参考文献：
  名称：

  A New 5-HT3 Receptor Ligand. II. Structure-Activity Analysis of 5-HT3 Receptor Agonist Action in the Gut.

  摘要：

  合成了几种对胃肠道蠕动具有兴奋作用的2-哌嗪基苯并噁唑衍生物，并研究了它们对豚鼠回肠收缩的影响。与5-HT3受体激动剂5-羟色胺和邻氯苯基双胍相比，季铵哌嗪基苯并噁唑结构具有受限的构象和立体结构。苯环、氮原子和末端胺的相对位置被认为是形成肠道5-HT3受体激动剂的药效团。在用大鼠进行的阻断血清素诱发反射性心动过缓[Bezold-Jarisch(B-J)反射]的试验中，每个合成化合物的诱发B-J反射的比例是不同的。这些结果表明，在这些5-HT3受体激动剂中，苯并噁唑环的取代基会影响大鼠的诱发B-J反射活性。

  DOI：

  10.1248/cpb.46.445

文献信息

• Analgesic Compounds, Compositions, and Uses Thereof
  申请人：Mannion James C.

  公开号：US20110224269A1

  公开（公告）日：2011-09-15

  The invention relates to compounds, compositions, and methods for diminishing pain in a subject in need thereof comprising administering the compounds and compositions herein described.

  这项发明涉及化合物、组合物和方法，用于减轻需要的受试者的疼痛，包括给予所述的化合物和组合物。
• NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION
  申请人：Seiwert Scott D.

  公开号：US20090269305A1

  公开（公告）日：2009-10-29

  The embodiments provide compounds of the general Formulae I, II, III, IV, V, VI, VII, and X, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

  该实施例提供了一般式I、II、III、IV、V、VI、VII和X的化合物，以及包括药物组合物在内的组合物，其中包括一种主体化合物。该实施例还提供了治疗方法，包括治疗丙型肝炎病毒感染的方法和治疗肝纤维化的方法，这些方法通常涉及向需要的个体施用一种主体化合物或组合物的有效量。
• [EN] DIARYLAMINE-SUBSTITUTED QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS<br/>[FR] QUINOLONES SUBSTITUÉES PAR DIARYLAMINE UTILES COMME INHIBITEURS DE L'OXYDE NITRIQUE SYNTHASE INDUCTIBLE.
  申请人：KALYPSYS INC

  公开号：WO2009029617A1

  公开（公告）日：2009-03-05

  Novel diarylamine-substituted quinolone compounds and pharmaceutical compositions, certain of which have been found to inhibit inducible NOS synthase have been discovered, together with methods of synthesizing and using the compounds including methods for the treatment of iNOS-mediated diseases in a patient by administering the compounds.

  已发现新的含有二芳胺基取代喹诺酮化合物和药物组合物，其中一些已被发现能抑制诱导型NOS合成酶，还包括合成和使用这些化合物的方法，包括通过给患者施用这些化合物治疗iNOS介导的疾病的方法。
• [EN] DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY<br/>[FR] DÉRIVÉS D'HÉTÉROARYLSULFONAMIDES, LEUR PRÉPARATION ET LEUR APPLICATION EN THÉRAPIE HUMAINE
  申请人：PF MEDICAMENT

  公开号：WO2012069503A1

  公开（公告）日：2012-05-31

  The present invention concerns derivatives of heteroarylsulfonamides, notably as blockers of Kv potassium channels, and more particularly of channels Kv1.5, Kv4.3 or Kv11.1, their application in clinical therapy and their preparation methods. These compounds correspond to the following general formula (I): where R1 represents one or more substituents of the phenyl core X such as: hydrogen, halogen, trifluoromethyl, trifluoromethoxy, linear or branched C1-C4 alkyl, or linear or branched C1-C4 alkoxy, A represents oxygen or sulphur, B represents nitrogen when n=1 or 2 and D represents −C(=O)-, or B represents CH when n=0 and D represents −CH2O− or when n=1 and D represents −O−, R2 represents a hydrogen, a methyl, a fluorine or chlorine atom or a methoxy, HetAr represents a pyridyl or quinolyl group, possibly substituted by a group such as a linear or branched C1-C4 alkyl, a linear or branched C1-C4 alkoxy, a halogen, or a trifluoromethyl, and to their pharmaceutically acceptable salts.

  本发明涉及杂环磺酰胺衍生物，特别是作为Kv钾通道的阻滞剂，更具体地是Kv1.5、Kv4.3或Kv11.1通道的阻滞剂，它们在临床治疗中的应用以及它们的制备方法。这些化合物对应于以下一般式（I）：其中R1代表苯环X的一个或多个取代基，如：氢、卤素、三氟甲基、三氟甲氧基、直链或支链C1-C4烷基，或直链或支链C1-C4烷氧基，A代表氧或硫，当n=1或2时，B代表氮，D代表−C(=O)-；当n=0时，B代表CH，D代表−CH2O−；当n=1时，B代表CH，D代表−O−，R2代表氢、甲基、氟或氯原子或甲氧基，HetAr代表可能被直链或支链C1-C4烷基、直链或支链C1-C4烷氧基、卤素或三氟甲基等取代的吡啶基或喹啉基，以及它们的药用可接受盐。
• DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY
  申请人：Dupont-Passelaigue Elisabeth

  公开号：US20130172326A1

  公开（公告）日：2013-07-04

  The present invention concerns derivatives of heteroarylsulfonamides, notably as blockers of Kv potassium channels, and more particularly of channels Kv1.5, Kv4.3 or Kv11.1, their application in clinical therapy and their preparation methods. These compounds correspond to the following general formula (I): where R1 represents one or more substituents of the phenyl core X such as: hydrogen, halogen, trifluoromethyl, trifluoromethoxy, linear or branched C 1 -C 4 alkyl, or linear or branched C 1 -C 4 alkoxy, A represents oxygen or sulphur, B represents nitrogen when n=1 or 2 and D represents —C(═O)—, or B represents CH when n=0 and D represents —CH 2 O— or when n=1 and D represents —O—, R2 represents a hydrogen, a methyl, a fluorine or chlorine atom or a methoxy, HetAr represents a pyridyl or quinolyl group, possibly substituted by a group such as a linear or branched C 1 -C 4 alkyl, a linear or branched C 1 -C 4 alkoxy, a halogen, or a trifluoromethyl, and to their pharmaceutically acceptable salts.

  本发明涉及杂环磺胺类衍生物，特别是作为Kv钾通道的阻滞剂，更具体地是Kv1.5、Kv4.3或Kv11.1通道的阻滞剂，它们在临床治疗中的应用以及它们的制备方法。这些化合物对应于以下一般式（I）：其中R1代表苯环X的一个或多个取代基，如：氢、卤素、三氟甲基、三氟甲氧基、直链或支链的C1-C4烷基，或直链或支链的C1-C4烷氧基，A代表氧或硫，当n=1或2时，B代表氮，D代表—C(═O)—，或当n=0时，B代表CH，D代表—CH2O—或当n=1时，D代表—O—，R2代表氢、甲基、氟或氯原子或甲氧基，HetAr代表可能被直链或支链的C1-C4烷基、直链或支链的C1-C4烷氧基、卤素或三氟甲基等取代的吡啶基或喹啉基，以及它们的药学上可接受的盐。